NCT03463135 - A Study to Assess Primarily the Tolerability and Safety of SAR439794 After Repeated Sublingual Daily Administration in Peanut Allergic Adult and Adolescent Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 7, 2018

Primary Completion Date

May 8, 2019

Study Completion Date

March 10, 2020

Conditions

Food Allergy

Interventions

DRUG

Glucopyranosyl Lipid A (GLA)

Pharmaceutical form:Colloidal aqueous dispersion Route of administration: Sublingual

DRUG

Sublingual Immuno Therapy (SLIT) Peanut Extract (PE)

Pharmaceutical form:Solution Route of administration: Sublingual

DRUG

Placebo for GLA

Pharmaceutical form:Colloidal aqueous dispersion Route of administration: Sublingual

DRUG

Placebo for SLIT PE

Pharmaceutical form:Solution Route of administration: Sublingual

Trial Locations (16)

21287

Investigational Site Number 8400002, Baltimore

29420

Investigational Site Number 8400010, Charleston

40215

Investigational Site Number 8400014, Louisville

45229

Investigational Site Number 8400011, Cincinnati

53792

Investigational Site Number 8400017, Madison

55402

Investigational Site Number 8400009, Minneapolis

Investigational Site Number 8400016, Minneapolis

72202

Investigational Site Number 8400004, Little Rock

80230

Investigational Site Number 8400013, Denver

92123

Investigational Site Number 8400008, San Diego

92691

Investigational Site Number 8400019, Mission Viejo

94305

Investigational Site Number 8400006, Stanford

95117

Investigational Site Number 8400020, San Jose

97504

Investigational Site Number 8400012, Medford

98105

Investigational Site Number 8400003, Seattle

02114

Investigational Site Number 8400001, Boston